Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of AK139 in moderate-to-severe atopic dermatitis
CTR20261113Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AK139 in atopic dermatitis (AD), sponsored by Akeso, Inc.. Started May 2026; status: active.
02
Drugs
AK139
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20261113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261113.